Sumatriptan - PharmaKB

Sumatriptan

Imitrex, Onzetra, Sumatriptan, Tosymra, Treximet, Zembrace (sumatriptan) is a small molecule pharmaceutical. Sumatriptan was first approved as Imitrex on 1992-12-28. It is used to treat cluster headache and migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 1F.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nervous system diseases	D009422

Trade Name

FDA

EMA

Imitrex, Imitrex statdose, Onzetra, Sumatriptan (discontinued: Alsuma, Imitrex, Imitrex statdose, Sumatriptan, Sumavel dosepro, Zecuity)

Combinations

Sumatriptan naproxen, Treximet (discontinued: Treximet)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Sumatriptan succinate

Tradename	Company	Number	Date	Products
ONZETRA XSAIL	Currax Pharmaceuticals	N-206099 RX	2016-01-27	1 products, RLD, RS
IMITREX	GSK	N-020132 RX	1995-06-01	3 products, RLD
IMITREX STATDOSE	GSK	N-020080 RX	1996-12-23	2 products, RLD, RS

Show 4 discontinued

Sumatriptan

Tradename	Company	Number	Date	Products
IMITREX	GSK	N-020626 RX	1997-08-26	2 products, RLD, RS

Show 1 discontinued

Naproxen sodium

Sumatriptan succinate

Tradename	Company	Number	Date	Products
TREXIMET	Currax Pharmaceuticals	N-021926 RX	2008-04-15	1 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
imitrex	New Drug Application	2024-03-22
migraine pack	ANDA	2017-01-13
migranow	unapproved drug other	2023-01-11
onzetra xsail	New Drug Application	2024-04-18
sumansetron	unapproved drug other	2023-01-11
sumatriptan	ANDA	2024-09-28
sumatriptan and naproxen sodium	ANDA	2023-12-29
sumatriptan succinate	ANDA	2024-08-14
sumatriptan succinate and naproxen sodium	NDA authorized generic	2022-01-19
sumavel dosepro	New Drug Application	2014-02-07

Show 3 more

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
migraine disorders	EFO_0003821	D008881	G43
cluster headache	HP_0012199	D003027	G44.00
juvenile arthritis	EFO_1002007	D001171	M08
ankylosing spondylitis	EFO_0003898	D013167	M45
rheumatoid arthritis	EFO_0000685	D001172	M06.9
headache	HP_0002315	D006261	R51
fever	HP_0001945	D005334	R50.9
inflammation	MP_0001845	D007249	—
osteoarthritis	EFO_0002506	D010003	M15-M19
bursitis	EFO_1000941	D002062	M71.9

Show 5 more

Agency Specific

FDA

EMA

No data

Patent Expiration

Patent	Expires	Flag	FDA Information
Sumatriptan Succinate, Zembrace Symtouch, Tonix Meds
10537554	2036-01-29		U-72
11364224	2036-01-29		U-72
Sumatriptan Succinate, Onzetra Xsail, Currax
10076614	2034-10-20	DP
10478574	2033-11-04		U-2404
8978647	2030-12-06	DP
9649456	2030-10-21	DP	U-1719, U-2010, U-2011
8899229	2030-08-18	DP
8550073	2029-10-22	DP
10076615	2029-07-30		U-2010, U-2011, U-2404
10722667	2028-12-30	DP
8875704	2028-04-07	DP	U-1809
10398859	2027-12-19	DP
10124132	2027-03-06	DP	U-1719, U-2010, U-2011
11571531	2026-02-23		U-1809
8590530	2025-09-15	DP	U-1809
9108015	2025-09-15	DP
7975690	2025-08-18	DP	U-1809
9119932	2024-04-23	DP
Sumatriptan Succinate, Zecuity, Teva Branded Pharm
9327114	2032-10-08	DP	U-1328
8983594	2030-11-19	DP	U-1328
8366600	2029-04-21		U-1327
9272137	2027-09-07	DP
7973058	2027-04-12		U-1328
8155737	2027-04-12		U-1328
8470853	2027-04-12		U-1328
8597272	2027-04-12	DP
9427578	2027-04-12	DP	U-1328
Sumatriptan, Tosymra, Tonix Meds
9211282	2031-07-19	DP	U-1719
9610280	2030-06-16	DP	U-1719
9974770	2030-06-16	DP	U-1719
10603305	2030-06-16	DP	U-1719
11337962	2030-06-16	DP	U-1719
8268791	2026-05-09	DP
8440631	2026-05-09	DP	U-1719
9283280	2026-05-09	DP
Sumatriptan Succinate, Alsuma, Meridian Medcl
7811254	2027-08-26	DP	U-1083
Sumatriptan Succinate, Sumavel Dosepro, Endo Ventures Ltd
7776007	2026-11-22	DP
7901385	2026-07-31	DP
8287489	2024-12-06	DP
Naproxen Sodium / Sumatriptan Succinate, Treximet, Currax
7332183	2025-10-02	DP	U-867, U-1719

ATC Codes

N: Nervous system drugs

— N02: Analgesics

— N02C: Antimigraine preparations

— N02CC: Selective serotonin (5ht1) agonists

— N02CC01: Sumatriptan

HCPCS

Code	Description
J3030	Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)

Clinical

Clinical Trials

132 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Migraine disorders	D008881	EFO_0003821	G43	12	11	34	17	29	101
Headache	D006261	HP_0002315	R51	—	7	7	7	20	41
Epilepsy	D004827	EFO_0000474	G40.9	—	1	1	1	1	4
Cognitive dysfunction	D060825	HP_0001268	G31.84	—	—	—	2	1	3
Emergencies	D004630	—	—	—	—	—	1	2	3
Post-dural puncture headache	D051299	—	—	—	—	—	2	1	3
Cluster headache	D003027	HP_0012199	G44.00	—	—	1	1	1	3
Premenstrual syndrome	D011293	—	N94.3	—	—	—	2	—	2
Post-traumatic headache	D051298	—	G44.3	—	1	—	1	—	2
Stroke	D020521	EFO_0000712	I63.9	—	—	—	1	—	1

Show 10 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Migraine without aura	D020326	EFO_0005296	G43.0	—	—	2	—	6	8
Migraine with aura	D020325	EFO_0005295	G43.1	—	1	1	—	3	5
Dysmenorrhea	D004412	HP_0100607	N94.6	—	—	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pain	D010146	EFO_0003843	R52	—	1	—	—	—	1
Vomiting	D014839	HP_0002013	R11.1	—	1	—	—	—	1
Nausea	D009325	HP_0002018	R11.0	—	1	—	—	—	1
Secondary headache disorders	D051271	—	—	—	1	—	—	—	1
Prescription drug overuse	D000067490	—	—	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	12	—	—	—	3	15
Therapeutic equivalency	D013810	—	—	2	—	—	—	—	2
Overweight	D050177	—	E66.3	1	—	—	—	—	1
Pharmacokinetics	D010599	—	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Inflammation	D007249	MP_0001845	—	—	—	—	—	2	2
Arthritis	D001168	HP_0001369	M05-M14	—	—	—	—	1	1
Tendinopathy	D052256	EFO_1001434	M77.9	—	—	—	—	1	1
Synovitis	D013585	EFO_0008997	M67.5	—	—	—	—	1	1
Spasm	D013035	—	M62.83	—	—	—	—	1	1
Radiculopathy	D011843	—	M54.1	—	—	—	—	1	1
Gout	D006073	EFO_0004274	M10	—	—	—	—	1	1
Flushing	D005483	—	R23.2	—	—	—	—	1	1
Rosacea	D012393	—	L71	—	—	—	—	1	1
Malnutrition	D044342	EFO_0008572	E40-E46	—	—	—	—	1	1

Show 2 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Sumatriptan
INN	sumatriptan
Description	Sumatriptan is a sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It is a sulfonamide and a member of tryptamines. It is functionally related to a N,N-dimethyltryptamine. It is a conjugate acid of a sumatriptan(1+).
Classification	Small molecule
Drug class	antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1

Identifiers

PDB	—
CAS-ID	103628-46-2
RxCUI	—
ChEMBL ID	CHEMBL128
ChEBI ID	10650
PubChem CID	5358
DrugBank	DB00669
UNII ID	8R78F6L9VO (ChemIDplus, GSRS)

Target

Agency Approved

HTR1D

HTR1B

Organism

Homo sapiens

Gene name

HTR1D

Gene synonyms

HTR1DA, HTRL

NCBI Gene ID

3352

Protein name

5-hydroxytryptamine receptor 1D

Protein synonyms

5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D

Uniprot ID

P28221

Mouse ortholog

Htr1d (15552)

5-hydroxytryptamine receptor 1D (Q8BUW7)

Alternate

HTR1E

HTR1A

HTR5A

HTR6

HTR7

HTR1F

Organism

Homo sapiens

Gene name

HTR1E

Gene synonyms

NCBI Gene ID

3354

Protein name

5-hydroxytryptamine receptor 1E

Protein synonyms

5-HT-1E, 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled, S31, Serotonin receptor 1E

Uniprot ID

Q9P1Y1

Mouse ortholog

—

Variants

No data

Financial

Revenue by drug

€

₣

Tosymra – Tonix Pharmaceuticals

Mock data
Subscribe for the real data

Tabular view

Estimated US medical usage

Sumatriptan

Naproxen

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Sumatriptan

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Tabular view

Trends

PubMed Central

Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data

Additional graphs summarizing 5,242 documents

View more details

Safety

Black-box Warning

Black-box warning for: Sumatriptan and naproxen sodium, Sumatriptan succinate and naproxen sodium, Treximet

Adverse Events

Top Adverse Reactions

Mock data
Subscribe for the real data

25,281 adverse events reported

View more details